Close Menu

synthetic biology

The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.

The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.

The researchers have launched a firm to commercialize the approach, which detects disease using protein networks encased in phospholipid bilayer membranes.